Novartis plans to file for new Lucentis indication in ROP
ROP is a rare and potentially blinding resulted due to abnormal development of retinal blood vessels in premature babies. The company has presented data from a Rainbow phase
China-based clinical-stage biotechnology company BoomRay Pharmaceuticals and Novartis Pharma have signed an exclusive worldwide licence deal for an undisclosed preclinical radioligand therapy (RLT) asset in a deal worth up to $900m.
THRUCOOL offers dedicated cold chain services to safeguard the integrity of pharmaceutical and healthcare shipments during air transportation. These include priority uplift and handling, quick ramp transfers at